Private Capital Advisors Inc. grew its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 9.8% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 42,546 shares of the medical research company’s stock after acquiring an additional 3,808 shares during the quarter. Thermo Fisher Scientific comprises 2.7% of Private Capital Advisors Inc.’s holdings, making the stock its 7th largest holding. Private Capital Advisors Inc.’s holdings in Thermo Fisher Scientific were worth $8,050,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. A.R.T. Advisors LLC bought a new stake in Thermo Fisher Scientific during the first quarter worth $3,158,000. Natixis grew its holdings in Thermo Fisher Scientific by 888.0% during the first quarter. Natixis now owns 81,058 shares of the medical research company’s stock worth $16,735,000 after buying an additional 72,854 shares in the last quarter. Ladenburg Thalmann Financial Services Inc. grew its holdings in Thermo Fisher Scientific by 5.2% during the first quarter. Ladenburg Thalmann Financial Services Inc. now owns 20,265 shares of the medical research company’s stock worth $4,182,000 after buying an additional 995 shares in the last quarter. LPL Financial LLC grew its holdings in Thermo Fisher Scientific by 8.5% during the first quarter. LPL Financial LLC now owns 62,099 shares of the medical research company’s stock worth $12,821,000 after buying an additional 4,883 shares in the last quarter. Finally, Kovack Advisors Inc. bought a new stake in Thermo Fisher Scientific during the first quarter worth $439,000. Hedge funds and other institutional investors own 85.96% of the company’s stock.
Several brokerages recently issued reports on TMO. Morgan Stanley upped their price target on Thermo Fisher Scientific from $242.00 to $254.00 and gave the stock an “overweight” rating in a report on Wednesday. Zacks Investment Research downgraded Thermo Fisher Scientific from a “hold” rating to a “sell” rating in a report on Tuesday, July 24th. Citigroup upped their price target on Thermo Fisher Scientific from $260.00 to $280.00 and gave the stock a “buy” rating in a report on Wednesday. Leerink Swann upped their price target on Thermo Fisher Scientific from $239.00 to $255.00 and gave the stock an “outperform” rating in a report on Thursday, July 26th. Finally, ValuEngine downgraded Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a report on Wednesday, June 20th. One equities research analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $259.91.
Shares of NYSE:TMO opened at $231.41 on Friday. The firm has a market capitalization of $98.31 billion, a price-to-earnings ratio of 24.38, a price-to-earnings-growth ratio of 1.78 and a beta of 1.12. The company has a quick ratio of 1.11, a current ratio of 1.58 and a debt-to-equity ratio of 0.67. Thermo Fisher Scientific Inc. has a 1 year low of $181.51 and a 1 year high of $249.95.
Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, July 25th. The medical research company reported $2.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.63 by $0.12. The firm had revenue of $6.08 billion during the quarter, compared to the consensus estimate of $5.90 billion. Thermo Fisher Scientific had a return on equity of 16.28% and a net margin of 10.36%. The business’s revenue for the quarter was up 21.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.30 EPS. On average, equities analysts forecast that Thermo Fisher Scientific Inc. will post 10.98 EPS for the current fiscal year.
Thermo Fisher Scientific declared that its Board of Directors has initiated a share repurchase plan on Friday, September 7th that allows the company to repurchase $2.00 billion in shares. This repurchase authorization allows the medical research company to buy up to 2.1% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company’s board of directors believes its shares are undervalued.
In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 125,520 shares of the company’s stock in a transaction on Monday, October 1st. The stock was sold at an average price of $247.50, for a total value of $31,066,200.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Marc N. Casper sold 50,000 shares of the company’s stock in a transaction on Monday, August 6th. The shares were sold at an average price of $233.95, for a total value of $11,697,500.00. Following the completion of the transaction, the chief executive officer now owns 320,122 shares of the company’s stock, valued at approximately $74,892,541.90. The disclosure for this sale can be found here. Insiders sold a total of 196,070 shares of company stock valued at $47,569,729 in the last 90 days. Corporate insiders own 0.49% of the company’s stock.
Thermo Fisher Scientific Profile
Thermo Fisher Scientific Inc provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.